Alamar Biosciences, Inc. operates as a proteomics company providing high-sensitivity protein biomarker analysis and precision proteomics solutions to support research and early disease detection. The company offers the NULISA proteomics platform for ultra-sensitive, multiplexed detection of protein biomarkers from small liquid biopsy specimens, and the ARGO HT system, a fully automated, high-throughput platform for biomarker profiling, validation, and clinical translation. Its services include integrated, cloud-based analytics, high-throughput sample processing, and pooled next-generation sequencing library preparation. The company develops and supplies assays for neurodegenerative disease research, including panels for brain-derived ptau217, ptau181, ptau231, and total tau. These products and services are intended for research use only. The company serves researchers from academic institutions, core laboratories, biopharmaceutical companies, and biotechnology companies. The company was founded in 2018 and is based in Fremont, California.
Exchange: NASDAQSector: Industrial Applications And Services